Kineret (Anakinra)

Anakinra is a competitive antagonist of the interleukin‑1 type I receptor. By binding to this receptor, it prevents the natural cytokines IL‑1α and IL‑1β from activating inflammatory signaling pathways, which leads to decreased production of downstream inflammatory mediators.

The dosage of Kineret is individualized by the prescribing clinician based on the specific indication, patient weight, renal function, and response to therapy. The prescriber determines the appropriate amount and frequency of subcutaneous administration.

Safety data for Anakinra in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks with their healthcare provider.

To order Kineret, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Kineret (Anakinra) is a daily subcutaneous IL‑1 receptor antagonist, whereas alternatives such as canakinumab are longer‑acting monoclonal antibodies administered monthly. Kineret offers rapid onset and flexibility in dosing adjustments, while longer‑acting agents may reduce injection frequency but have different safety and cost profiles.

Kineret should be stored in a refrigerator at 2‑8 °C (36‑46 °F). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. Do not use the medication if it has been exposed to temperatures outside this range.

Kineret is given by subcutaneous injection, typically into the abdomen, thigh, or upper arm. The injection site should be rotated with each dose to minimize local reactions. Patients or caregivers should be trained on proper aseptic technique and disposal of used needles.

The most serious risks include severe infections such as sepsis, neutropenia or other significant reductions in white blood cells, and hypersensitivity reactions that can be life‑threatening. Patients should be monitored closely for signs of infection, fever, or allergic symptoms.

Kineret is contraindicated in individuals with known hypersensitivity to Anakinra or any component of the formulation. It should also be avoided in patients with active, uncontrolled infections, and caution is advised for those receiving live vaccines or other potent immunosuppressants.